NZ628515A - Antiviral compounds with a dibenzooxaheterocycle moiety - Google Patents

Antiviral compounds with a dibenzooxaheterocycle moiety

Info

Publication number
NZ628515A
NZ628515A NZ628515A NZ62851513A NZ628515A NZ 628515 A NZ628515 A NZ 628515A NZ 628515 A NZ628515 A NZ 628515A NZ 62851513 A NZ62851513 A NZ 62851513A NZ 628515 A NZ628515 A NZ 628515A
Authority
NZ
New Zealand
Prior art keywords
compounds
disclosed
dibenzooxaheterocycle
moiety
treating
Prior art date
Application number
NZ628515A
Other languages
English (en)
Inventor
Vidya Ramdas
Advait Arun Joshi
Moloy Manoj Banerjee
Amit Kumar Das
Deepak Sahebrao Walke
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of NZ628515A publication Critical patent/NZ628515A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ628515A 2012-02-10 2013-02-08 Antiviral compounds with a dibenzooxaheterocycle moiety NZ628515A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN147KO2012 2012-02-10
IN1017KO2012 2012-09-04
PCT/IB2013/051062 WO2013118097A1 (en) 2012-02-10 2013-02-08 Antiviral compounds with a dibenzooxaheterocycle moiety

Publications (1)

Publication Number Publication Date
NZ628515A true NZ628515A (en) 2016-06-24

Family

ID=54259033

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ628515A NZ628515A (en) 2012-02-10 2013-02-08 Antiviral compounds with a dibenzooxaheterocycle moiety
NZ628445A NZ628445A (en) 2012-02-10 2013-02-09 Antiviral compounds with a heterotricycle moiety

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ628445A NZ628445A (en) 2012-02-10 2013-02-09 Antiviral compounds with a heterotricycle moiety

Country Status (14)

Country Link
US (2) US9073943B2 (enExample)
EP (2) EP2812326A1 (enExample)
JP (1) JP6034883B2 (enExample)
KR (1) KR20140129034A (enExample)
CN (1) CN104136433B (enExample)
AU (2) AU2013217224B2 (enExample)
BR (1) BR112014019584A8 (enExample)
CA (2) CA2862755A1 (enExample)
IN (2) IN2014MN01547A (enExample)
MX (1) MX2014009546A (enExample)
NZ (2) NZ628515A (enExample)
SG (2) SG11201404475TA (enExample)
WO (2) WO2013118097A1 (enExample)
ZA (1) ZA201405490B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012283609B2 (en) 2011-07-09 2016-09-29 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR102794564B1 (ko) * 2016-04-08 2025-04-15 듀폰스페셜티머터리얼스코리아 유한회사 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
UY38705A (es) * 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
CN114605310B (zh) * 2022-04-09 2024-05-07 都创(上海)医药科技股份有限公司 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
JPWO2005012284A1 (ja) 2003-07-31 2007-09-27 大正製薬株式会社 4,5−ジヒドロナフト[1,2−b]チオフェン誘導体
CA2539403C (en) 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
ATE372995T1 (de) 2003-11-07 2007-09-15 Hoffmann La Roche Benzo(b)(1,4)dioxepinderivate
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
GB0501964D0 (en) 2005-01-31 2005-03-09 Arrow Therapeutics Ltd Chemical compounds
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
BRPI0619733A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2680507A1 (en) 2006-10-13 2008-04-24 Xtl Biopharmaceuticals Ltd. Compounds and methods for treatment of hcv
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200906826A (en) 2007-06-12 2009-02-16 Genelabs Tech Inc Anti-viral inhibitors and methods of use
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
WO2009034390A1 (en) 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
KR101396696B1 (ko) 2007-10-10 2014-05-16 노파르티스 아게 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도
CN101998952B (zh) 2008-02-12 2014-10-08 百时美施贵宝公司 丙型肝炎病毒抑制剂
AU2009214977A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis C virus inhibitors
KR101492672B1 (ko) 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2280973T3 (pl) 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BRPI1013643A2 (pt) 2009-02-10 2016-04-19 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
EA201190224A1 (ru) 2009-03-27 2012-03-30 Пресидио Фармасьютикалс, Инк. Ингибиторы гепатита c, содержащие конденсированные кольца
HUE027755T2 (en) 2009-03-27 2016-11-28 Merck Sharp & Dohme Inhibitors of hepatitis C virus replication
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CA2768637A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CN102883718A (zh) 2009-12-24 2013-01-16 顶点制药公司 用于治疗或预防黄病毒感染的类似物
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011109037A1 (en) 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011151652A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
WO2011151651A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
CA2802067A1 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
KR20140045903A (ko) 2010-08-04 2014-04-17 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2808291A1 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
MX2013002927A (es) 2010-09-24 2013-05-30 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
BR112013007696A2 (pt) 2010-09-29 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, usos do referido composto e da referida composição
KR101835474B1 (ko) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety

Also Published As

Publication number Publication date
US9073943B2 (en) 2015-07-07
KR20140129034A (ko) 2014-11-06
CA2862755A1 (en) 2013-08-15
AU2013217229B2 (en) 2017-03-02
BR112014019584A8 (pt) 2017-07-11
NZ628445A (en) 2016-05-27
IN2014MN01548A (enExample) 2015-05-08
JP2015510512A (ja) 2015-04-09
CN104136433B (zh) 2016-05-04
EP2812326A1 (en) 2014-12-17
CA2862330A1 (en) 2013-08-15
ZA201405490B (en) 2015-10-28
CN104136433A (zh) 2014-11-05
SG11201404475TA (en) 2014-08-28
WO2013118102A1 (en) 2013-08-15
AU2013217224B2 (en) 2017-04-06
US9073942B2 (en) 2015-07-07
AU2013217229A1 (en) 2014-08-21
MX2014009546A (es) 2015-10-29
US20150010504A1 (en) 2015-01-08
WO2013118097A1 (en) 2013-08-15
JP6034883B2 (ja) 2016-11-30
BR112014019584A2 (enExample) 2017-06-20
AU2013217224A1 (en) 2014-08-21
US20150010505A1 (en) 2015-01-08
EP2812327A1 (en) 2014-12-17
SG11201404365SA (en) 2014-10-30
IN2014MN01547A (enExample) 2015-05-08

Similar Documents

Publication Publication Date Title
NZ628445A (en) Antiviral compounds with a heterotricycle moiety
EA201301158A1 (ru) Противовирусные соединения
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2010081082A3 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2012008221A (es) Inhibidores de virus flaviviridae.
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2012000959A (es) Inhibidores de los virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
CA2753382C (en) Hepatitis c virus inhibitors
NZ748966A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
WO2011041713A3 (en) Piperazinyl antiviral agents
MY202109A (en) Viral replication inhibitors
TN2012000358A1 (en) Hepatitis c virus inhibitors
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
MY194294A (en) Novel viral replication inhibitors
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
PH12016500389A1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
NZ610331A (en) Viral polymerase inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 FEB 2018 BY IN-LEGAL LIMITED

Effective date: 20170110

LAPS Patent lapsed